# Nirogy Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nirogy-therapeutics

- Industry: Biotechnology
- Headquarters: Natick, US
- Website: www.nirogytx.com
- Total disclosed funding: $17M
- Latest round: Series A (Jan 24, 2021)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2013, Nirogyone Therapeutics develops novel small molecules to target cellular transport. The company was awarded a USD 2 million NIH/NCI SBIR grant to develop dual monocarboxylate transport inhibitors (dMCTi) for Triple Negative Breast Cancer (TNBC) in September 2020. Nirogy Therapeutics, Inc. has 4 employees across all its locations.  

The Company's products are SLCTs (Solute Carrier Transporters) which help to control the import and export of various molecules cells in our body and MCTs (Monocarboxylate Transporters) focus on blocking lactate export, which kills cancer cells. 

Nirogy Therapeutics plans to use the proceeds to advance its drug discovery platform to generate a pipeline of small-molecule drugs designed to target the solute carrier family of transporter proteins (SLCTs) embedded in the cell membrane.

## Funding rounds

- Series A, Jan 24, 2021, $17M — Sante Ventures, Sporos Bioventures

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A
- Sporos Bioventures (https://capitalatlas.ai/funds/sporos-bioventures) — Series A